Immunai news
Immunai, a New York-based biotech company, today announced a $215M Series B, increasing the company’s total funding to date to $295M. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation.
“We have made great progress towards our core mission of understanding the immune system, which we believe is essential to finding the answers to human health and disease,&rdq
New York City- and Tel Aviv-based Immunai said the acquisition would allow it to expand its target discovery and drug development capabilities and that Nebion`s experience curating public gene expression datasets would help Immunai grow its Annotated Multiomic Immunological Cell Atlas, or AMICA.
"As with other machine learning endeavors like autonomous driving or NLP, having the right data is key," Noam Solomon, Immunai CEO and cofounder, said in a statement. "We`re thrilled to bring
Immunai has taken some important steps toward its quest to map the entire immune system by completing its second acquisition this year and bolstering its management and board with new executive and entrepreneurial expertise.
Immunai has acquired the Swiss-based biocuration and data integration company Nebion for an undisclosed sum. The deal should extend Immunai’s target discovery and drug development capabilities with Nebion’s curated datasets, discovery tools, and servic
Immunai, a New York and Tel Aviv-based biotech company, today announced that it has been recognized as part of Fast Company’s World Changing Ideas Awards. The awards honor the businesses, policies, projects, and concepts that are actively engaged and deeply committed to pursuing innovation when it comes to solving health and climate crises, social injustice, or economic inequality. Immunai has been recognized with an hono
Immunai, a New York and Tel Aviv-based biotech company, announced its acquisition of Dropprint Genomics, a San Francisco-based single-cell genomics software company. Immunai is also expanding its executive leadership team and scientific advisory board with experts in immunology, single-cell technologies and machine learning. Both the acquisition and new hires will advance the company’s work in single cell functional genomics with the goal of better sup
Shortly after raising $60 million to fuel its artificial intelligence work, aimed at digitally charting the human body’s immune system, Immunai announced it has acquired the single-cell sequencing software startup Dropprint Genomics.
Immunai, meanwhil
With a recently closed $60 million funding round, the acquisition of software company Dropprint Genomics, and additions to its leadership team, immune profiling firm Immunai is looking to expand its functional genomics capabilities to
Immunai, a New York and Tel Aviv based biotech company, announced today $60M in funding, increasing the company’s total funding-to-date to over $80M. Immunai integrates multi-omic single-cell analytics and machine learning to identify novel immunological insights that lead to the discovery and development of more effective and targeted immunotherapies. The Series A round was led by Schusterman Family Investments, Duquesne Family Office, Catalio Capital
Today, Immunai launches out of stealth to map the entire immune system for better detection, diagnosis, and treatment of disease. Leveraging single-cell technologies and machine learning algorithms, Immunai has mapped out millions of immune cells and their functions, building the largest proprietary data set in the world for clinical immunological data. The company is also announcing $20M in seed funding, which will be use